Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus + gemcitabine in advanced pancreatic cancer
ACTRN12611000643976Phase 2Terminated
- Sponsor
- HeCOG
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus and gemcitabine in pancreatic cancer (PC) (6 arms), sponsored by HeCOG. Primary endpoints: Maximum tolerated dose and feasibility and 6-month progression-free survival. Started May 2009; status: terminated.
02
Drugs
temsirolimusgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ACTRN12611000643976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000643976.